Takehiro Shiinoki

Dr. Takehiro Shiinoki

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Physica Medica
Verified
Journal Article
Closed access
KFKoya Fujimoto
Koya Fujimoto
TSTakehiro Shiinoki
Takehiro Shiinoki
YYYuki Yuasa
Yuki Yuasa
HHHideki Hanazawa
Hideki Hanazawa
KSKeiko Shibuya
Keiko Shibuya

8 July 2016 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
TSTakehiro Shiinoki
Takehiro Shiinoki
SKShinji Kawamura
Shinji Kawamura
TUTakuya Uehara
Takuya Uehara
YYYuki Yuasa
Yuki Yuasa
KFKoya Fujimoto
Koya Fujimoto
KSKeiko Shibuya
Keiko Shibuya
A combined system comprising the TrueBeam linear accelerator and a new real-time, tumor-tracking radiotherapy system, SyncTraX, was installed in our institution. The goals of this study were to assess the capability of SyncTraX in measuring the position of a fiducial marker using color fluoroscopic images, and to evaluate the dosimetric and geometric accuracy of respiratory-gated radiotherapy using this combined system for the simple geometry. For the fundamental evaluation of respiratory-gated radiotherapy using SyncTraX, the following were performed: 1) determination of dosimetric and positional characteristics of sinusoidal patterns using a motor-driven base for several gating windows; 2) measurement of time delay using an oscilloscope; 3) positional verification of sinusoidal patterns and the pattern in the case of a lung cancer patient; 4) measurement of the half-value layer (HVL in mm AL), effective kVp, and air kerma, using a solid-state detector for each fluoroscopic condition, to determine the patient dose. The dose profile in a moving phantom with gated radiotherapy having a gating window ?4?mm was in good agreement with that under static conditions for each photon beam. The total time delay between TrueBeam and SyncTraX was <227?ms for each photon beam. The mean of the positional tracking error was <0.4?mm for sinusoidal patterns and for the pattern in the case of a lung cancer patient. The air-kerma rates from one fluoroscopy direction were 1.93?0.01 , 2.86?0.01 , 3.92?0.04 , 5.28?0.03 , and 6.60?0.05?mGy/min for 70, 80, 90, 100, and 110 kV X-ray beams at 80 mA, respectively. The combined system comprising TrueBeam and SyncTraX could track the motion of the fiducial marker and control radiation delivery with reasonable accuracy; therefore, this system provides significant dosimetric improvement. However, patient exposure dose from fluoroscopy was not clinically negligible. PACS number(s): 87.53.Bn, 87.55.km, 87.55.Qr

31 October 2019 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
KJKai Jiang
Kai Jiang
FFFumitake Fujii
Fumitake Fujii
TSTakehiro Shiinoki
Takehiro Shiinoki
The present note addresses the development of a lung tumor position predictor to be used in dynamic tumor tracking radiotherapy, abbreviated as DTT-RT. As there exists 50–500 ms positioning lag in the control of the multi-leaf collimator (MLC) of commercial medical linear accelerators, prediction of future lung tumor position with sufficiently long prediction horizon is inevitable for the successful implementation of DTT-RT. The present article proposes a lung tumor position predictor, which is classified as a nonlinear autoregressive model with exogenous input (NARX). The proposed predictor was trained using seven lung tumor motion trajectories of patients who underwent respiratory gated radiotherapy at Yamaguchi University Hospital. We considered three different prediction horizons, 600 ms, 800 ms and 1 s, which were sufficiently long to compensate for the possible positioning control lag of the MLC. A patient-specific model corresponding to an intended prediction horizon was obtained by training it using the selected tumor motion trajectory with the specified horizon. Accordingly, we obtained three NARX predictors for a single patient. We calculated two performance metrics: the RMS prediction errors and the rate of coverage of the entire tumor trajectory defined by the number of samples of the measured tumor position which was inside the 4 mm cube centered at the corresponding predicted tumor position. The latter quantifies the feasibility of the predictors to generate future gating cubes in the implementation of DTT-RT. The (mean standard deviation) values of the rates of 600 ms, 800 ms and 1 s prediction horizon calculated using the proposed NARX predictors were %, % and %, respectively.

6 July 2018 in Actuators
Verified
Journal Article
Open access
PDF file
FFFumitake Fujii
Fumitake Fujii
KTKen’ichi Tatebatake
Ken’ichi Tatebatake
KMKohei Morita
Kohei Morita
TSTakehiro Shiinoki
Takehiro Shiinoki
This paper proposes an enhancement of the Bouc–Wen hysteresis model to capture the frequency-dependent hysteretic behavior of a thin bimorph-type piezoelectric actuator which also exhibits odd harmonic oscillation (OHO) at specific input frequencies. The odd harmonic repetitive controller has recently been proposed to compensate for the hysteresis, and attenuates the OHO of the piezoelectric actuator for which the hysteresis nonlinearity is regarded as a disturbance. This paper proposes an alternate treatment of the hysteresis compensation with the attenuation of the OHO observed at some input frequencies. It will be shown that the proposed compensator fully utilizes the mathematical structure of the enhanced Bouc–Wen model proposed in this paper to compensate the hysteresis and to attenuate the OHO. The results of the hysteresis compensation experiment illustrate the excellent performance of the proposed control system, especially at the frequencies where OHO is conspicuous.

8 October 2019 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
YYYuki Yuasa
Yuki Yuasa
TSTakehiro Shiinoki
Takehiro Shiinoki
RORyota Onizuka
Ryota Onizuka
KFKoya Fujimoto
Koya Fujimoto
This study was conducted to estimate the organ equivalent dose and effective imaging dose for four‐dimensional cone‐beam computed tomography (4D‐CBCT) using a Monte Carlo simulation, and to evaluate the excess absolute risk (EAR) of secondary cancer incidence. The EGSnrc/BEAMnrc were used to simulate the on‐board imager (OBI) from the TrueBeam linear accelerator. Specifically, the OBI was modeled based on the percent depth dose and the off‐center ratio was measured using a three‐dimensional (3D) water phantom. For clinical cases, 15 lung and liver cancer patients were simulated using the EGSnrc/DOSXYZnrc. The mean absorbed doses to the lung, stomach, bone marrow, esophagus, liver, thyroid, bone surface, skin, adrenal glands, gallbladder, heart, intestine, kidney, pancreas and spleen, were quantified using a treatment planning system, and the equivalent doses to each organ were calculated. Subsequently, the effective dose was calculated as the weighted sum of the equivalent dose, and the EAR of the secondary cancer incidence was determined for each organ with the use of the biologic effects of ionizing radiation (BEIR) VII model. The effective doses were 3.9 ± 0.5, 15.7 ± 2.0, and 7.3 ± 0.9 mSv, for the lung, and 4.2 ± 0.6, 16.7 ± 2.4, and 7.8 ± 1.1 mSv, for the liver in the respective cases of the 3D‐CBCT (thorax, pelvis) and 4D‐CBCT modes. The lung EARs for males and females were 7.3 and 10.7 cases per million person‐years, whereas the liver EARs were 9.9 and 4.5 cases per million person‐years. The EAR increased with increasing time since radiation exposure. In clinical studies, we should use 4D‐CBCT based on consideration of the effective dose and EAR of secondary cancer incidence.

25 July 2022 in Brachytherapy
Verified
Journal Article
Closed access
HTHidenobu Tachibana
Hidenobu Tachibana
YWYusuke Watanabe
Yusuke Watanabe
SKShogo Kurokawa
Shogo Kurokawa
TMTakuya Maeyama
Takuya Maeyama
THTomoyuki Hiroki
Tomoyuki Hiroki
TATetsuo Akimoto
Tetsuo Akimoto